Who we are
We reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
At Novartis, we use science-based innovation to adress some of society‘s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
The Innovative Medicines Division has two business units:
Novartis Oncology focuses on patented treatments for a variety of cancers and rare diseases.
Novartis Pharmaceuticals focuses on patented treatments in the areas of ophthalmology; immunology, hepatology and dermatology; neuroscience; respiratory; and cardio-metabolic.
With its Surgical and Vision Care businesses, Alcon offers one of the world’s widest selections of eye care devices – from sophisticated equipment for delicate eye surgery, to a wide portfolio of advanced contact lenses.
In 2018, Novartis announced the intention to spin off Alcon, pending approval from shareholders and regulators.
Sandoz offers patients and healthcare professionals high-quality, affordable generics and biosimilars.
Novartis Business services (NBS)
consolidates support services across our organization, helping drive efficiency, simplification, standardization and quality.
Novartis technical operations (NTO)
handles manufacturing of innovative medicines and Sandoz products. NTO helps us optimize resource allocation and capacity planning across our production sites.
Corporate functions support the enterprise in specific areas of expertise, including finance, human resources, legal and communications.
Research and development (R&D)
The Novartis Institutes for BioMedical Research (NIBR) is the innovation engine of Novartis. NIBR focuses on discovering new drugs that can change the practice of medicine.
The Global Drug Development (GDD) organization oversees the development of new medicines discovered by our researchers and partners.
The greatest strength of Novartis is our people, whose diversity, energy and creativity are crucial to our success.